Previous 10 | Next 10 |
COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has suc...
COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its ...
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combin...
Tuesday, April 12 th @ 12:30 pm ET COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunothera...
Evaxion Biotech ADS press release (NASDAQ:EVAX): Q4 GAAP EPS of -$0.39 misses by $0.10. Cash and cash equivalents of $32.2 million at end of 2021, combined with €7.0 million (approximately $7.7 million) proceeds from draw down of European Investment Bank loan, expected to fund operatio...
Completed follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) raising net proceeds of $24.9 million after deducting underwriting discounts, commissions and other offering expenses Announced clinical trial collaboration and su...
Evaxion Biotech (NASDAQ:EVAX) has strengthened its management team with Bo Karmark as its CFO and Jesper Nyegaard Nissen as its COO. Bo Karmark, most recently served as CFO for Aquaporin A/S, a water technology company. Jesper Nyegaard Nissen, most recently worked on&...
COPENHAGEN, Denmark, March 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies to improve the lives of patients with cancer and infectious diseases. Evaxion Biotech a...
COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patient...
COPENHAGEN, Denmark, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publicatio...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...